Artiva Biotherapeutics (NASDAQ:ARTV) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Artiva Biotherapeutics (NASDAQ:ARTV – Free Report) from a sell rating to a strong sell rating in a research report released on Saturday morning,Wall Street Zen reports.

ARTV has been the subject of several other research reports. Needham & Company LLC downgraded shares of Artiva Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 27th. TD Cowen lowered shares of Artiva Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 27th. Jefferies Financial Group cut shares of Artiva Biotherapeutics from a “buy” rating to a “hold” rating and set a $4.00 price objective on the stock. in a research report on Thursday, October 29th. Wedbush cut shares of Artiva Biotherapeutics from an “outperform” rating to a “neutral” rating and set a $4.00 price objective on the stock. in a research report on Tuesday, October 27th. Finally, HC Wainwright reissued a “buy” rating on shares of Artiva Biotherapeutics in a research note on Friday, October 2nd. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $24.80.

View Our Latest Stock Analysis on Artiva Biotherapeutics

Artiva Biotherapeutics Stock Performance

Shares of NASDAQ ARTV opened at $3.96 on Friday. The stock’s fifty day simple moving average is $6.51 and its 200 day simple moving average is $7.93. Artiva Biotherapeutics has a 52-week low of $2.96 and a 52-week high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.01). Analysts predict that Artiva Biotherapeutics will post -2.74 EPS for the current year.

Insiders Place Their Bets

In other news, insider Subhashis Banerjee sold 8,222 shares of the company’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $12.01, for a total value of $98,746.22. Following the transaction, the insider owned 142,047 shares in the company, valued at $1,705,984.47. This represents a 5.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Fred Aslan sold 23,463 shares of the company’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $7.20, for a total value of $168,933.60. Following the completion of the transaction, the chief executive officer owned 1,519,606 shares in the company, valued at $10,941,163.20. This represents a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 136,619 shares of company stock valued at $1,081,019. 1.80% of the stock is owned by insiders.

Institutional Trading of Artiva Biotherapeutics

Institutional investors have recently made changes to their positions in the stock. State of Wyoming purchased a new position in Artiva Biotherapeutics during the second quarter valued at approximately $45,000. State Street Corp lifted its position in Artiva Biotherapeutics by 2.5% in the 3rd quarter. State Street Corp now owns 339,761 shares of the company’s stock worth $2,419,000 after buying an additional 8,233 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in Artiva Biotherapeutics in the 2nd quarter worth approximately $144,000. Spark Investment Management LLC purchased a new stake in Artiva Biotherapeutics in the 2nd quarter worth approximately $160,000. Finally, Dimensional Fund Advisors LP purchased a new stake in Artiva Biotherapeutics in the 1st quarter worth approximately $131,000.

About Artiva Biotherapeutics

(Get Free Report)

Artiva Biotherapeutics is a San Diego-based clinical-stage biotechnology company developing allogeneic, or donor-derived, natural killer (NK) cell therapies. Its approach is designed to provide ready-made cell treatments for patients with cancer and autoimmune diseases. The company’s lead candidate, AlloNK (also known as AB-101), is an investigational NK cell therapy being studied in combination with antibody treatments. Artiva is evaluating its potential in autoimmune conditions and in cancers, including B-cell malignancies.

Further Reading

Analyst Recommendations for Artiva Biotherapeutics (NASDAQ:ARTV)

Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.